Final-Program-ATS-2023-AP.vp

WEDNESDAY • MAY 24

341

511 Predictors of Adherence to Asthma Controller Medication Among Pediatric, Adolescent, and Adult Patients in the United States/ A.E. Cameron, San Diego, CA 512 Predictors of Exacerbations Among Pediatric, Adolescent, and Adult Patients With Asthma in the United States/ A. Cameron, San Diego, CA 513 Changes in Asthma Medications, Symptom Control and Urgent Health Care for Asthma in Australia Between 2012 and 2021, From Nationally Representative Web Surveys/ H. Reddel, Glebe, Australia Hyperactivity Disorder Symptoms, Perceptions of Respiratory Compromise, and Illness Representations in Minority Children With Asthma/ N. Fruchter, Bronx, NY 515 The Role of Biologics in Decreasing Asthma Exacerbation Rate: A Systematic Review and Meta-analysis/ R. Ali, Harrisburg, PA 516 Impact of Extrafine Formulation Single-inhaler Triple Therapy on Asthma Control and Health-related Quality of Life After Three Months of Treatment in Patients With 514 The Associations Between Attention-Deficit 518 Omalizumab, Mepolizumab, and Dupilumab Are Associated With Differing Lung Function Trajectories in Patients With Moderate to Severe Asthma/ A. Akenroye, Boston, MA 519 Provider Perspectives on Cross-system Prescribing of High-risk Medications: Implications for Policy and Organizational Support/ K.R. Gillmeyer, Boston, MA 520 Generic Vs. Brand-name Fluticasone-Salmeterol in the Prevention of COPD Exacerbations/ W.B. Feldman, Boston, MA 521 Impact of COVID-19 Pandemic on Pneumococcal and Influenzae Vaccination Among Medicare and Medicaid Beneficiaries in the United States in 2020/ H. Singh, Milwaukee, WI Asthma: Trimaximize - A Real-world View From Germany, United Kingdom, Austria and Denmark/ C. Gessner, Leipzig, Germany 517 Comparative Effectiveness of Dupilumab and Omalizumab in Improving Exacerbations in Individuals With Allergic Asthma/ T. Nopsopon, Boston, MA

BEHAVIORAL • CLINICAL POSTER DISCUSSION SESSION

D102 HIGHLIGHTS OF EPIDEMIOLOGIC AND CLINICAL RESEARCH IN BEHAVIORAL SCIENCES 12:00 p.m. - 2:00 p.m. Walter E. Washington Convention Center Room 151 B (Street Level) Poster Viewing 12:00-12:45 Discussion 12:45-2:00 Chairing: E.K. Kross, MD, Seattle, WA M.P. Kerlin, MD, MS, Philadelphia, PA J. Hart, MD, MS, Philadelphia, PA 501 Trends in the Epidemiology of Chronic Obstructive Pulmonary Disease (COPD) in Never Smokers in Ontario/ A.J. Blazer, Toronto, Canada 502 National Prevalence and Risk Factors for Loneliness and Social Isolation Among Adults With Chronic Obstructive Pulmonary Disease/ A. Suen, San Francisco, CA 503 Mobility and Medication Usage Trends Surrounding High-Rescue Days in Patients With Chronic Obstructive Pulmonary Disease/ A. Allen, San Diego, CA 504 Incidence and Association of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Amongst Patients With Substance Use Disorders - A National Burden of COPD/ A. Raheem, Galveston, TX 505 Obstructive Sleep Apnea as a Risk Factor During Hospitalization for Acute Exacerbation of Chronic Obstructive Pulmonary Disease - a National Inpatient Sample Study/ J.R. De La Fuente, New Brunswick, NJ 506 Mapping EQ5D Utilities From Forced Vital Capacity and Diffusing Capacity in Fibrotic Interstitial Lung Disease/ A.W. Wong, Vancouver, Canada 507 Early Interstitial Lung Disease in Rheumatoid Arthritis: An Observational Study of Risk Factors and Mortality in Ontario, Canada/ L. Fidler, Toronto, Canada 508 Impact of Cannabis Use Disorder on In-hospital Outcomes Among Smokers With Acute Myocardial Infarction: Insights From National Inpatient Sample 2019/ M.C.V.B. Gudiwada, Chicago, IL 509 Association Between Exclusive Marijuana Use and Asthma Severity: Results From a Nationally Representative Study/ T. Kaplan, Annapolis, MD 510 Characteristics, Healthcare Resource Use and Costs Among High-Risk Patients With COPD in the United States/ A. Cameron, San Diego, CA

ATS 2023 • Washington, DC